APVACAssociation des Porteurs de Valves Artificielles Cardiaques
References in periodicals archive ?
immatics uses its unique antigen discovery engine XPRESIDENT to generate a warehouse of tumor-associated peptides (TUMAPs) from which the most suitable for each patient will be selected based on transcriptomic and peptidomic analysis to create the first of two APVACs applied to the patient.
The clinical trial is being accompanied by an extensive biomarker program led by the Association of Cancer Immunotherapy (CIMT), a non-profit organization dedicated to the advancement of cancer vaccines, and immatics to confirm the mechanism-of-action and to identify biomarker signature candidates predicting which patients are most likely to benefit from treatment with APVACs.
The project aims to show that APVACs are well tolerated and induce a strong and specific immune response against cancer.